ClinicalTrials.gg
RecruitingNCT07222215CAPELAUpdated Aug 26, 2026

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

A Phase 2 interventional study of Capecitabine and Elacestrant in Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer and Breast Cancer, sponsored by Kristina A. Fanucci. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Kristina A. Fanucci · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Planned enrollment
46th of 227
297 · median 54
Started
2026
with 4 others
Phase 2
121 of 233
20 open now
Primary completion
2029-12
later than 35 of 40 live
Registered
229th of 233
by date

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 46th largest by planned enrollment of the 227 interventional ones that give a count, is one of 5 that started in 2026, is one of 121 in phase 2, reaches primary completion later than 35 of the 40 other live ones, and was the 229th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medication in the class of therapy called CDK 4/6 inhibitors, including palbociclib, ribociclib, or abemaciclb.

The names of the study drugs involved in this study are:

  • Elacestrant (a type of selective estrogen receptor degrader)
  • Capecitabine (a type of fluoropyrimidine antimetabolite)
Read the detailed description

This is a Phase II, multi-center, open-label, randomized study comparing a combination of two drugs, capecitabine and elacestrant, to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medication in the class of therapy called CDK 4/6 inhibitors, including palbociclib, ribociclib, or abemaciclb.

Participants will be randomized into one of two study groups: Arm A Capecitabine and Elacestrant versus Arm B Capecitabine alone. Randomization means a participants is placed into a study group by chance.

The U.S. Food and Drug Administration (FDA) has approved capecitabine as a treatment option for advanced estrogen receptor-positive (ER+) Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.

The FDA has approved elacestrant for metastatic breast cancer with an ESR1 mutation. Elacestrant is not FDA approved for participants whose cancer does not have ESR1 mutation and it is possible elacestrant may not be as effective or effective at all in participants whose tumors do not have an ESR1 mutation.

The FDA has not approved Elacestrant and Capecitabine to be given together.

The research study procedures include screening for eligibility, in-clinic visits, questionnaires, blood tests, urine tests, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, and electrocardiograms (ECGs).

It is expected that about 297 people will take part in this research study.

Stemline, a Menarini Group Company, is supporting this research study by providing the study drugs, elacestrant, and funding. This study is also being supported by Johns Hopkins University on behalf of the Translational Breast Cancer Research Consortium (TBCRC).

03

Conditions studied

  • Estrogen-receptor-positive Breast Cancer
  • Metastatic Breast Cancer
  • Breast Cancer
  • Hormone Receptor Positive Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • HER2- Breast Cancer
  • ESR1 Gene Mutation
  • ER Wildtype
  • Breast Neoplasms

Browse trials for

Keywords

  • Advanced Estrogen Receptor-Positive Breast Cancer
  • Metastatic Breast Cancer
  • Breast cancer
  • Hormone receptor positive breast cancer
  • Advanced Human Epidermal Growth Factor Receptor 2 negative breast cancer
  • HER2- Breast Cancer
  • ESR1 gene mutation
  • ER wildtype
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed estrogen receptor-positive (ER+), -negative or locally recurrent unresectable (advanced) invasive breast cancer. ER and HER2 measurements should be performed according to institutional guidelines in a CLIA-approved setting. ER must be ≥ 10% on the most recent in which receptor testing was performed. Cutoff values for positive/negative HER2 staining should be in accordance with current ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines.
  • Participants must have standard of care ctDNA sequencing testing documenting ESR1 and TP53 mutation status. In patients without ESR1 mutation, this result must be from within 3 months.

    • ESR1 mutations that are considered pathogenic are: E380Q, V422del, S436P, L536H, L536P, L536R, Y537C, Y537D, Y537N, Y537S, D538G
    • TP53 mutations that are considered pathogenic as determined by a CLIA certified laboratory
  • Women or men age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of capecitabine in combination with elacestrant participants \<18 years of age are excluded from this study
  • Women must be , which is defined as any of the following:

    • Age ≥ 60 years
    • Age \< 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) and FSH and estradiol in the postmenopausal range per local normal range
    • Premenopausal women who have been on a GnRH agonist for at least three consecutive months prior to study entry are eligible. Women in this group MUST remain on the GnRH agonist for the duration of protocol treatment.
    • Status-post bilateral oophorectomy or total hysterectomy after adequate healing post-surgery
  • Must have measurable or evaluable disease by 1.1. Must have progressed on at least one line of endocrine therapy in the metastatic setting or recurred on or within one year of endocrine therapy
  • Unrestricted number of prior endocrine therapies (with or without targeted treatment) are allowed in the advanced disease setting. If a patient recurred on or within one year of adjuvant endocrine therapy, it would be counted as one .
  • Prior CDK4/6 inhibition is required (in adjuvant or metastatic disease), unless a CDK4/6 inhibitor is (CDK4/6 inhibitor in combination with endocrine treatment is considered as one line of endocrine treatment).
  • Participants must have remained on a prior endocrine treatment alone or in combination with a CDK4/6 inhibitor in the metastatic setting without progression for at least 6 months prior to study entry. This regimen does not need to be the most recent regimen prior to study entry. If patients have progressed on adjuvant endocrine treatment and have not received treatment in the metastatic setting, they must have progressed after at least two years of adjuvant endocrine treatments.
  • Prior alpelisib with endocrine treatment is allowed (considered as a line of endocrine treatment).
  • Prior everolimus with endocrine treatment is allowed (considered a line of endocrine treatment).
  • Prior capivasertib with endocrine treatment is allowed (considered a line of endocrine treatment)
  • Prior fulvestrant is permitted. Prior SERM (tamoxifen, lasofoxifene) is permitted. Neither prior oral SERDs nor other next generation oral endocrine therapies (such as PROTACS) are permitted.
  • No prior chemotherapy regimen or ADC is allowed in the metastatic setting.
  • Participants may have received radiotherapy for palliative purposes but must not be experiencing grade >1 treatment-related toxicities at study entry and must have completed treatment > 14 days prior to registration.
  • PS 0-1
  • Adequate hematological, liver, and kidney function, as defined below:

    • > 1,500/µL
    • > 100,000/µL
    • > 9 g/dL (transfusion is allowed to meet this criterion) Total \< 1.5 x institutional upper limit or normal () or \< 3 institutional ULN in the presence of documented Gilbert's syndrome
    • (SGOT)/ALT (SGPT) \< 2.5 x institutional ULN, or ≤ 5 institutional ULN for subjects with documented metastatic disease to the liver
    • > 50 mL/min/1.73 m2
  • Women of childbearing age, women who are made postmenopausal through use of GNRH agonists, and men must agree to use adequate for the duration of protocol treatment and for at least 6 months after the last dose of capecitabine.
  • Premenopausal women must have a negative serum or urine pregnancy test. Pregnancy testing does not need to be pursued in female participants who are:

    • Age > 60 years; or
    • Age \< 60 with intact uterus and amenorrhea for 12 consecutive months or more AND estrogen (estradiol) and FSH levels are within postmenopausal range; or
    • Status-post bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation
  • Participants must be able to swallow and retain oral medication.
  • Ability to understand and the willingness to sign a written document.
  • -infected participants must have well-controlled HIV on ART, defined as:

    1. Participants on ART must have a ≥350 cells/mm3 at the time of screening.
    2. Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening.
    3. It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months.
    4. Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1) and agree to continue ART throughout the study. The combination ART regimen must not contain any antiretroviral medications that interact with inhibitors/inducers/substrates.

Note: No HIV testing is required at screening unless mandated by local health Authority.

  • Participants who are positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load before allocation.

Note: Participants should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.Hepatitis B screening tests are not required unless:

  • Known history of HBV infection
  • As mandated by local health authority Participants with history of infection are eligible if HCV viral load is undetectable at screening.

Note: Participants must have completed curative antiviral therapy at least 4 weeks before allocation.

Hepatitis C screening tests are not required unless:

  • Known history of HCV infection
  • As mandated by local health authority

Exclusion criteria

Exclusion Criteria:

  • Participants who have had endocrine and/or biologic therapy \< 14 days prior to entering the study or those who have not recovered from any prior treatment-related toxicities (must recover to no more than grade 1; alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 toxicity not constituting a safety risk based on investigator's judgment are acceptable). This is to minimize risk of drug-drug interactions and clarify etiology of future toxicities.
  • Participants who are receiving concurrent therapy with other agents. This is to minimize risk of drug-drug interactions and clarify etiology of future toxicities.
  • Rapidly progressive, symptomatic, visceral spread of disease placing participant at risk of life- threatening complications in the short term. It is likely that these patients will not benefit from this regimen.
  • History of dihydropyrimidine dehydrogenase (DPD) deficiency. Patients with this deficiency are prone to significant toxicity from capecitabine.
  • Participants with active . Treated brain metastases that are asymptomatic and do not require systemic for management of symptoms are allowed if they have received SRS (7-day washout) or WBRT (14-day washout) or asymptomatic untreated brain metastases measuring \<1cm. Patients with are not eligible. It is unlikely that these patients will benefit from this regimen.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring systemic therapy, cardiovascular disease including: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ Classification Class II), or serious cardiac arrhythmia requiring medication, uncontrolled diabetes mellitus, gastrointestinal disorders potentially affecting the absorption of elacestrant, inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or total gastric resection, or psychiatric illness/social situations that would limit compliance with study requirements. Active or active infection. Ability to comply with study requirements is to be assessed by each investigator at the time of screening for study participation. This could increase risk of toxicity from treatment and potentially decrease adherence to study protocol.
  • Individuals with a history of a different are ineligible except for the following circumstances:

    • (1) Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. These cases should be discussed with the sponsor-investigator prior to enrollment.
    • (2) Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: ductal carcinoma in situ of the breast, cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin. History of prior malignancy puts patients at risk of recurrence from their prior malignancy or progression of a second malignancy which would complicate interpretation of the end points of this trial.
  • Ongoing treatment with drugs that are sensitive substrates of P-glycoprotein (dabigatran, digoxin, fexofenadine) or BRCP (rosuvastatin, sulfasalazine). These drugs have potential drug-drug interactions with the study agents.
  • Treatment with strong inhibitors within 2 weeks before first study treatment administration or five elimination half-lives, whichever is longest and cannot be replaced.
  • Medical conditions requiring concomitant administration of medications with a narrow therapeutic window metabolized by CYP3A and for which a dose reduction cannot be considered. See Appendix D for a list of medications that are CYP3A substrates. These drugs have potential drug-drug interactions with the study agents.
  • Female participants lactating or nursing. The safety of these medications in pregnancy or breast feeding patients is unknown.

Both men and women of all races and ethnic groups are eligible for this trial.

Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
297 participants (estimated)

Study arms

  • Experimental
    Arm A: Capecitabine + Elacestrant

    Participants will be randomized 1:1, enrolled, and stratified based on the receipt of one or greater than one prior lines of endocrine therapy in the metastatic setting, presence or absence of visceral disease, presence or absence of ESR1 mutation, and presence or absence of p53 mutation. * Baseline visit with assessments * Imaging every 9 weeks for 27 weeks, then every 12 weeks * Cycle 1 through End of Treatment (21-day cycles): * Days 1 - 14: Predetermined dose of Capecitabine 2x daily for 14 days followed by 7 days off * Days 1 - 21: Predetermined dose of Elacestrant 1x daily * Follow up: every 6 months after end of treatment

    Drug: Capecitabine · Drug: Elacestrant

  • Experimental
    Arm B: Capecitabine Monotherapy

    Participants will be randomized 1:1, enrolled, and stratified based on the receipt of one or greater than one prior lines of endocrine therapy in the metastatic setting, presence or absence of visceral disease, presence or absence of ESR1 mutation, and presence or absence of p53 mutation. * Baseline visit with assessments * Imaging every 9 weeks for 27 weeks, then every 12 weeks * Cycle 1 through End of Treatment (21-day cycles): --Days 1 - 14: Predetermined dose of Capecitabine 2x daily for 14 days followed by 7 days off * Follow up: every 6 months after end of treatment

    Drug: Capecitabine

  • Experimental
    Optional switch after progression on Arm B Capecitabine monotherapy: Elacestrant Monotherapy

    For Arm B participants with ESR1 mutation, at the time of progression on Capecitabine participants have the option to continue on trial and switch to single agent Elacestrant monotherapy. -Imaging every 9 weeks for 27 weeks, then every 12 weeks Through End of Treatment (21-day cycles): --Days 1 - 21: Predetermined dose of Elacestrant 1x daily -Follow up: every 6 months after end of treatment

    Drug: Elacestrant

Interventions

  • A fluoropyrimidine carbamate, tablet taken orally, per standard of care.

    Also known as: Xeloda

  • A selective estrogen receptor degrader, tablet taken orally, per standard of care

    Also known as: RAD1901, Elacestrant Dihydrochloride, RAD1901 - 2 HCl, C30H40Cl2N2O2

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) in ESR1 mutant population

    PFS based on the Kaplan-Meier method is defined as the time from study randomization to disease progression per RECIST 1.1 or death. Patients alive without disease progression are censored at the date of last disease evaluation.

    Time frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles.

  2. Progression Free Survival (PFS) in intention to treat (ITT) population

    PFS based on the Kaplan-Meier method is defined as the time from study randomization to disease progression per RECIST 1.1 or death. Patients alive without disease progression are censored at the date of last disease evaluation.

    Time frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles.

Secondary outcomes

  1. Overall Survival (OS) in ESR1 mutant population

    Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from randomization to death due to any cause or censored at date last known alive.

    Time frame: Follow up or other contact every 2 months for 24 months until time of second progression, then every 6 months for 5 years

  2. Objective Response Rate in ESR1 mutant population

    The objective response rate is defined as the rate of patients with a complete response or partial response, calculated using RECIST 1.1. The best overall response is the best response recorded from the start of treatment until disease progression/recurrence.

    Time frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles

  3. Clinical benefit rate (CBR) in ESR1 mutant population

    The clinical benefit rate is defined as the rate of patients with a complete response (CR), partial response (PR), or stable disease (SD) ≥24 weeks, calculated using RECIST 1.1.

    Time frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles

  4. Second progression event (PFS2) in ESR1 mutant population

    PFS2 based on the Kaplan-Meier method is defined as the time from study randomization to second disease progression, according to RECIST 1.1, or death after first progression.

    Time frame: Follow up or other contact every 2 months for a total of 24 months or until progressive disease

  5. Overall survival (OS) in ITT population

    Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from randomization to death due to any cause or censored at date last known alive.

    Time frame: Follow up or other contact every 2 months for 24 months until time of second progression, then every 6 months for 5 years

  6. Objective Response Rate in ITT population

    The objective response rate is defined as the rate of patients with a complete response or partial response, calculated using RECIST 1.1.

    Time frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles

  7. Clinical benefit rate (CBR) in ITT population

    The clinical benefit rate is defined as the rate of patients with a complete response (CR), partial response (PR), or stable disease (SD) ≥24 weeks, calculated using RECIST 1.1.

    Time frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles

  8. Second progression event (PFS2) in ITT population

    PFS2 based on the Kaplan-Meier method is defined as the time from study randomization to second disease progression, according to RECIST 1.1, or death after first progression.

    Time frame: Follow up or other contact every 2 months for a total of 24 months or until progressive disease

  9. Safety and tolerability of capecitabine in combination with elacestrant

    Assessment of toxicities and lab values categorized and graded according to CTCAE v5.0

    Time frame: Assessment will occur once per cycle (each cycle is 21 days) for the first 9 cycles, then once every other cycle starting with cycle 10

  10. Impact of treatment with capecitabine plus elacestrant versus capecitabine alone on quality of life

    evaluation with PRO-CTCAE and FACT-ES survey instruments

    Time frame: Once every 2 cycles (each cycle is 21 days) for the first 4 cycles, every 3 months for months 3-12 on trial, then every 6 months for months 12+ on trial

Other outcomes

  1. Overall survival (OS) ESR1 mutation not detected population

    Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from randomization to death due to any cause or censored at date last known alive.

    Time frame: Follow up or other contact every 2 months for 24 months until time of second progression, then every 6 months for 5 years

  2. Progression-free survival rate (PFS)

    PFS based on the Kaplan-Meier method is defined as the time from study randomization to disease progression per RECIST 1.1 or death. Patients alive without disease progression are censored at the date of last disease evaluation.

    Time frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles

  3. Second progression event (PFS2)

    PFS2 based on the Kaplan-Meier method is defined as the time from study randomization to second disease progression, according to RECIST 1.1, or death after first progression.

    Time frame: Follow up or other contact every 2 months for a total of 24 months or until progressive disease

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 46 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 46 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2025
First posted
Oct 29, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Dec 1, 2029
CompletionEst.
Oct 1, 2030
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07222215
Lead sponsor
Kristina A. Fanucci
Collaborators
Stemline Therapeutics, Inc., Johns Hopkins University, Translational Breast Cancer Research Consortium, Menarini Group, Gateway for Cancer Research, Terri Brodeur Breast Cancer Foundation
Responsible party
Kristina A. Fanucci (Sponsor-Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Oct 29, 2025
Start date
Jan 16, 2026
Primary completion
Dec 1, 2029 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Aug 26, 2026

Study contacts

Kristina Fanucci, MD
Contact
Kristina_Fanucci@dfci.harvard.edu
617-632-3800
Kristina Fanucci, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Elacestrant

Start the discussion